PHBI (Pharmagreen Biotech) Beta: 1.5782 (As of Jul. 01, 2026)


What is Pharmagreen Biotech Beta?

Pharmagreen Biotech PHBI Beta is 1.5782 as of Jul. 01, 2026.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-01), Pharmagreen Biotech's Beta is 1.5782.

Pharmagreen Biotech  (OTCPK:PHBI) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Pharmagreen Biotech Beta Related Terms

Pharmagreen Biotech Beta Historical Data

* Premium members only.

The historical data trend for Pharmagreen Biotech's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmagreen Biotech Beta Chart

Pharmagreen Biotech Annual Data
Trend Apr08 Apr09 Sep18 Sep19 Sep20 Sep21 Sep22
Beta
Get a 7-Day Free Trial 8.25 6.50 3.14 1.07 1.24

Pharmagreen Biotech Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.61 1.24 1.15 1.20 1.37

PHBI vs DVLP, CSTF, BLMS: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmagreen Biotech's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmagreen Biotech Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmagreen Biotech's Beta distribution charts can be found below:

* The bar in red indicates where Pharmagreen Biotech's Beta falls into.


Pharmagreen Biotech Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.5782 mean?
Pharmagreen Biotech (PHBI) has a Beta of 1.5782 as of Jul. 01, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Pharmagreen Biotech and its competitors.
Is Pharmagreen Biotech's Beta too high?
Pharmagreen Biotech's current Beta is 1.5782.
How does Pharmagreen Biotech's Beta compare to DVLP and CSTF?
Pharmagreen Biotech's Beta of 1.5782 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Pharmagreen Biotech and its competitors. Pharmagreen Biotech's current Beta is 1.5782. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmagreen Biotech stock overvalued right now?
Pharmagreen Biotech (PHBI) has a current Beta of 1.5782. The current Beta is 1.5782. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Pharmagreen Biotech (PHBI), the current Beta is 1.5782 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharmagreen Biotech Business Description

Address 112 North Curry Street, Carson, NV, USA, 89703
Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.